SD:专项披露公告
04/25 06:11 (美东)
6-K:美国FDA批准武田ENTYVIO®(vedolizumab)皮下注射用于中度至重度活动性克罗恩病的维持治疗
04/19 06:15 (美东)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外国发行人报告
04/15 06:33 (美东)
TAKEDA PHARMACEUTICAL CO LTD | SC 13D/A:超过5%持股股东披露文件(修正)-Takeda Pharmaceutical Company Limited(4.8%)
04/10 06:12 (美东)
TAKEDA PHARMACEUTICAL CO LTD | SC 13D/A:超过5%持股股东披露文件(修正)-Takeda Pharmaceutical Company Limited(5.4%)
04/01 06:21 (美东)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外国发行人报告
03/27 06:38 (美东)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外国发行人报告
02/09 06:09 (美东)
TAKEDA PHARMACEUTICAL CO LTD | SC 13G/A:超过5%持股股东披露文件(修正)-BlackRock, Inc.(7.7%)
02/06 09:43 (美东)
TAKEDA PHARMACEUTICAL CO LTD | SC 13G/A:超过5%持股股东披露文件(修正)-Sumitomo Mitsui Trust Holdings, Inc.(5.5%)
02/05 06:27 (美东)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外国发行人报告(业绩相关)
02/02 06:20 (美东)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外国发行人报告
02/01 06:21 (美东)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外国发行人报告(业绩相关)
02/01 06:12 (美东)
TAKEDA PHARMACEUTICAL CO LTD | 4:持股变动声明-股东 TAKEDA PHARMACEUTICAL CO LTD
01/25 06:14 (美东)
TAKEDA PHARMACEUTICAL CO LTD | SC 13D/A:超过5%持股股东披露文件(修正)-Takeda Pharmaceutical Company Limited(6.6%)
01/25 06:14 (美东)
TAKEDA PHARMACEUTICAL CO LTD | SC 13G:超过5%持股股东披露文件-Takeda Pharmaceutical Company Limited(5.2%),Takeda Ventures, Inc(5.2%)
01/19 00:00 (美东)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外国发行人报告
01/16 00:00 (美东)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外国发行人报告(业绩相关)
2023/12/14 06:01 (美东)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外国发行人报告(业绩相关)
2023/11/30 06:01 (美东)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外国发行人报告
2023/11/13 06:05 (美东)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外国发行人报告(业绩相关)
2023/10/30 06:02 (美东)
暂无数据
暂无数据